Thorsten Ruf

1.6k total citations · 1 hit paper
20 papers, 807 citations indexed

About

Thorsten Ruf is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Thorsten Ruf has authored 20 papers receiving a total of 807 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 6 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Thorsten Ruf's work include Lung Cancer Treatments and Mutations (12 papers), Lung Cancer Research Studies (8 papers) and Lung Cancer Diagnosis and Treatment (5 papers). Thorsten Ruf is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Lung Cancer Research Studies (8 papers) and Lung Cancer Diagnosis and Treatment (5 papers). Thorsten Ruf collaborates with scholars based in Switzerland, United States and Poland. Thorsten Ruf's co-authors include Rafał Dziadziuszko, Walter Bordogna, Vlatka Smoljanović, Solange Peters, Jin Seok Ahn, Tony Mok, Rafael Rosell, Shirish M. Gadgeel, Magalie Hilton and D. Ross Camidge and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Thorsten Ruf

20 papers receiving 790 citations

Hit Papers

Updated overall survival and final progression-free survi... 2020 2026 2022 2024 2020 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study
    2020 414 citations Tony Mok, D. Ross Camidge et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thorsten Ruf Switzerland 9 498 388 209 180 148 20 807
Weiqiang Yin China 18 828 1.7× 272 0.7× 70 0.3× 148 0.8× 149 1.0× 51 1.1k
S. Srinivas United States 13 527 1.1× 282 0.7× 137 0.7× 410 2.3× 264 1.8× 38 816
Amanda Kirane United States 14 248 0.5× 224 0.6× 85 0.4× 96 0.5× 50 0.3× 41 600
Thomas d’Amato United States 12 581 1.2× 195 0.5× 94 0.4× 163 0.9× 82 0.6× 19 878
Pierre‐Jean Souquet France 9 499 1.0× 409 1.1× 69 0.3× 327 1.8× 159 1.1× 9 765
Kei Takamura Japan 12 561 1.1× 453 1.2× 39 0.2× 180 1.0× 107 0.7× 40 773
Martina Crysandt Germany 12 143 0.3× 175 0.5× 97 0.5× 122 0.7× 60 0.4× 50 519
Carina Hillenbach Switzerland 7 319 0.6× 383 1.0× 110 0.5× 111 0.6× 65 0.4× 11 630
John Syrios Greece 12 141 0.3× 297 0.8× 183 0.9× 77 0.4× 63 0.4× 22 574

Countries citing papers authored by Thorsten Ruf

Since Specialization
Citations

This map shows the geographic impact of Thorsten Ruf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thorsten Ruf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thorsten Ruf more than expected).

Fields of papers citing papers by Thorsten Ruf

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thorsten Ruf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thorsten Ruf. The network helps show where Thorsten Ruf may publish in the future.

Co-authorship network of co-authors of Thorsten Ruf

This figure shows the co-authorship network connecting the top 25 collaborators of Thorsten Ruf. A scholar is included among the top collaborators of Thorsten Ruf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thorsten Ruf. Thorsten Ruf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kassir, Nastya, et al.. (2024). Exposure‐Response Relationships for Pralsetinib in Patients with RET‐Altered Thyroid Cancer or RET Fusion‐Positive Nonsmall Cell Lung Cancer. The Journal of Clinical Pharmacology. 64(6). 685–696. 2 indexed citations
2.
Horinouchi, Hidehito, Benjamin Solomon, Yi‐Long Wu, et al.. (2024). OA13.04 ALINA Safety Results: Adjuvant Alectinib vs Chemotherapy in Patients with Resected ALK+ Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 19(10). S39–S39. 1 indexed citations
3.
Nishio, Makoto, Yi‐Long Wu, Fabrice Barlési, et al.. (2024). Health-related quality of life (HRQoL) results for adjuvant alectinib vs chemotherapy in patients with resected ALK+ non-small cell lung cancer (NSCLC): Data from ALINA.. Journal of Clinical Oncology. 42(16_suppl). 8006–8006. 1 indexed citations
4.
Doz, François, Michela Casanova, Kyung‐Nam Koh, et al.. (2024). Abstract CT039: Alectinib in children and adolescents with solid or CNS tumors harboring ALK-fusions: Data from the iMATRIX Alectinib Phase I/II open-label, multi-center study. Cancer Research. 84(7_Supplement). CT039–CT039. 1 indexed citations
5.
Dziadziuszko, Rafał, Nir Peled, Tony Mok, et al.. (2023). High-dose alectinib for RET fusion-positive non-small cell lung cancer in the Blood First Assay Screening Trial. Współczesna Onkologia. 27(4). 217–223. 1 indexed citations
6.
Solomon, Benjamin, Jin Seok Ahn, Rafał Dziadziuszko, et al.. (2023). LBA2 ALINA: Efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell lung cancer (NSCLC). Annals of Oncology. 34. S1295–S1296. 38 indexed citations
7.
8.
Dziadziuszko, Rafał, Solange Peters, Thorsten Ruf, et al.. (2022). Clinical experience and management of adverse events in patients with advanced ALK-positive non-small-cell lung cancer receiving alectinib. ESMO Open. 7(6). 100612–100612. 14 indexed citations
9.
Mok, Tony, D. Ross Camidge, Shirish M. Gadgeel, et al.. (2020). Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Annals of Oncology. 31(8). 1056–1064. 414 indexed citations breakdown →
10.
Peters, Solange, Tony Mok, Shirish M. Gadgeel, et al.. (2020). Updated overall survival (OS) and safety data from the randomized, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC.. Journal of Clinical Oncology. 38(15_suppl). 9518–9518. 19 indexed citations
11.
Wolf, Jennifer Moriatis, Åslaug Helland, In‐Jae Oh, et al.. (2019). OA02.07 Phase 3 ALUR Study of Alectinib in Pretreated ALK+ NSCLC: Final Efficacy, Safety and Targeted Genomic Sequencing Analyses. Journal of Thoracic Oncology. 14(10). S210–S210. 6 indexed citations
12.
Morcos, Peter N., Katrijn Bogman, Stanislas Hubeaux, et al.. (2017). Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies. Cancer Chemotherapy and Pharmacology. 79(3). 559–568. 33 indexed citations
13.
14.
Bentley, Darren, et al.. (2011). No Evidence of QT Prolongation With Supratherapeutic Doses of Aleglitazar. Journal of Cardiovascular Pharmacology. 59(3). 288–297. 2 indexed citations
15.
Ruf, Thorsten, et al.. (2000). Lack of Pharmacokinetic Drug-Drug Interaction between Orlistat and Cerivastatin. Clinical Drug Investigation. 19(1). 71–73. 7 indexed citations
16.
Ruf, Thorsten, Jens Lüdemann, Herbert Posival, et al.. (1998). Alterations of cross-bridge kinetics in human atrial and ventricular myocardium. Cardiovascular Research. 40(3). 580–590. 29 indexed citations
17.
18.
Holubarsch, Christian, Thorsten Ruf, Daniel J. Goldstein, et al.. (1996). Existence of the Frank-Starling Mechanism in the Failing Human Heart. Circulation. 94(4). 683–689. 174 indexed citations
19.
Holubarsch, Christian, R. Schneider, Burkert Pieske, et al.. (1995). Positive and Negative Inotropic Effects ofdl-Sotalol andd-Sotalol in Failing and Nonfailing Human Myocardium Under Physiological Experimental Conditions. Circulation. 92(10). 2904–2910. 26 indexed citations
20.
Ruf, Thorsten, et al.. (1992). Ca-agonism: Energetically superior to PDE-inhibition in a chronic heart failure model. Journal of Molecular and Cellular Cardiology. 24. S73–S73. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Weiqiang Yin Breakdown of academic impact, for papers by S. Srinivas Breakdown of academic impact, for papers by Amanda Kirane Breakdown of academic impact, for papers by Thomas d’Amato Breakdown of academic impact, for papers by Pierre‐Jean Souquet Breakdown of academic impact, for papers by Kei Takamura Breakdown of academic impact, for papers by Martina Crysandt Breakdown of academic impact, for papers by Carina Hillenbach Breakdown of academic impact, for papers by John Syrios
Rankless by CCL
2026